ArticleJournal of the Intensive Care Society2019
Novel use of Cytosorb™ haemadsorption to provide biochemical control in liver impairment.
Article in Journal of the Intensive Care Society, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 54 citations in OpenAlex.
- Trial
- Cast nephropathy in the ICU: Early recognition and extracorporeal strategies to improve outcomes.Journal of intensive medicine · 2026Review
- The international, prospective CytOSorbJournal of intensive medicine · 2025Article
- Article
- Reply to Riva et al. Comment on "Gaspari et al. Blood Purification in Hepatic Dysfunction after Liver Transplant or Extensive Hepatectomy: Far from the Best-Case Scenarios.Journal of clinical medicine · 2025Article
- The use of CytoSorb hemoadsorption in critically ill patients: a narrative review.Frontiers in medicine · 2025Review
- The COSMOS Registry of CytoSorb Hemoadsorption Therapy in Critically Ill Patients: Protocol for an International, Prospective Registry.JMIR research protocols · 2024Observational
- Correlation of bilirubin and toxic bile acids in critically ill patients with cholestatic liver dysfunction and adsorber application.Scientific reports · 2024Article
- Use of the CytoSorb adsorber in patients with acute-on-chronic liver failure.Scientific reports · 2024Observational
- Blood Purification in Hepatic Dysfunction after Liver Transplant or Extensive Hepatectomy: Far from the Best-Case Scenarios.Journal of clinical medicine · 2024Article
- Effective Apixaban removal using hemoadsorption during emergent open-heart surgery: a case report and narrative literature review.Journal of cardiothoracic surgery · 2024Review
- Hemoadsorption Therapy for Critically Ill Patients with Acute Liver Dysfunction: A Meta-Analysis and Systematic Review.Biomedicines · 2023Review
- Liver-Support Therapies in Critical Illness-A Comparative Analysis of Procedural Characteristics and Safety.Journal of clinical medicine · 2023Article
- Liver replacement therapy with extracorporeal blood purification techniques current knowledge and future directions.World journal of clinical cases · 2023Review
- Artificial Liver Support with CytoSorb and MARS in Liver Failure: A Retrospective Propensity Matched Analysis.Journal of clinical medicine · 2023Article
- Immunomodulation by Hemoadsorption-Changes in Hepatic Biotransformation Capacity in Sepsis and Septic Shock: A Prospective Study.Biomedicines · 2022Article
- Polymyxin B engineered polystyrene-divinylbenzene microspheres for the adsorption of bilirubin and endotoxin.RSC advances · 2021Article
- Kinetics of Bilirubin and Ammonia Elimination during Hemadsorption Therapy in Secondary Sclerosing Cholangitis Following ECMO Therapy and Severe COVID-19.Biomedicines · 2021Article
- Therapeutic Modulation of the Host Defense by Hemoadsorption with CytoSorbInternational journal of molecular sciences · 2021Article
- Hemoadsorption in 'Liver Indication'-Analysis of 109 Patients' Data from the CytoSorb International Registry.Journal of clinical medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We describe the use of Cytosorb™, a synthetic extracorporeal haemoperfusion adsorption column, in the management of two patients with drug induced cholestasis and a third with alcoholic hepatitis and subsequent acute on chronic liver failure. Cytosorb was used in these patients to remove bilirubin and bile acids by supporting impaired excretory hepatic function, alleviating symptoms with the intention of serving as a bridge to endogenous recovery. The first two cases demonstrate favourable biochemical and symptomatic responses; the third case demonstrated a good biochemical response but subsequently died from the complications of multiple organ failure. These cases suggest Cytosorb™ be evaluated as an adjunct to support liver excretory functions in other arenas, such as acute liver failure or overdose. It remains unclear whether extracorporeal therapies removing liver toxins allow faster or more complete spontaneous recovery of endogenous function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.